$ALXO
ALX ONCOLOGY HOLDINGS INC

2022 Q1 Form 10-Q Financial Statement

#000095017022008499 Filed on May 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.674M $4.360M
YoY Change 76.01% 196.6%
% of Gross Profit
Research & Development $17.07M $9.849M
YoY Change 73.35% 157.15%
% of Gross Profit
Depreciation & Amortization $58.00K $5.000K
YoY Change 1060.0% -95.58%
% of Gross Profit
Operating Expenses $24.75M $14.21M
YoY Change 74.18% 140.94%
Operating Profit -$24.75M -$14.21M
YoY Change 74.18% 171.04%
Interest Expense $225.0K $25.00K
YoY Change 800.0% -111.63%
% of Operating Profit
Other Income/Expense, Net -$11.00K -$2.000K
YoY Change 450.0% -128.57%
Pretax Income -$24.53M -$14.19M
YoY Change 72.95% 160.28%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$24.53M -$14.19M
YoY Change 72.95% 160.08%
Net Earnings / Revenue
Basic Earnings Per Share -$0.60
Diluted Earnings Per Share -$604.0K -$354.2K
COMMON SHARES
Basic Shares Outstanding 40.63M 40.06M
Diluted Shares Outstanding 40.62M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $316.6M $429.9M
YoY Change -26.36% 309.43%
Cash & Equivalents $159.1M $429.9M
Short-Term Investments $157.5M
Other Short-Term Assets $4.929M $2.500M
YoY Change 97.16% 108.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $321.5M $432.3M
YoY Change -25.63% 302.54%
LONG-TERM ASSETS
Property, Plant & Equipment $1.338M $47.00K
YoY Change 2746.81% -94.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $25.11M
YoY Change
Other Assets $15.70M $536.0K
YoY Change 2829.85% 168.0%
Total Long-Term Assets $42.15M $583.0K
YoY Change 7130.02% -41.7%
TOTAL ASSETS
Total Short-Term Assets $321.5M $432.3M
Total Long-Term Assets $42.15M $583.0K
Total Assets $363.7M $432.9M
YoY Change -15.99% 299.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.133M $7.350M
YoY Change -30.16% 267.5%
Accrued Expenses $9.746M $2.700M
YoY Change 260.96% 200.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $429.0K $100.0K
YoY Change 329.0% -88.89%
Total Short-Term Liabilities $15.31M $14.13M
YoY Change 8.34% 253.23%
LONG-TERM LIABILITIES
Long-Term Debt $175.0K $100.0K
YoY Change 75.0% -97.87%
Other Long-Term Liabilities $4.772M $297.0K
YoY Change 1506.73% -50.5%
Total Long-Term Liabilities $4.772M $297.0K
YoY Change 1506.73% -94.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.31M $14.13M
Total Long-Term Liabilities $4.772M $297.0K
Total Liabilities $20.08M $14.43M
YoY Change 39.19% 55.12%
SHAREHOLDERS EQUITY
Retained Earnings -$226.5M -$132.7M
YoY Change 70.69%
Common Stock $570.7M $551.2M
YoY Change 3.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $343.6M $418.5M
YoY Change
Total Liabilities & Shareholders Equity $363.7M $432.9M
YoY Change -15.99% 299.36%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$24.53M -$14.19M
YoY Change 72.95% 160.08%
Depreciation, Depletion And Amortization $58.00K $5.000K
YoY Change 1060.0% -95.58%
Cash From Operating Activities -$20.67M -$5.135M
YoY Change 302.61% -42.71%
INVESTING ACTIVITIES
Capital Expenditures $589.0K $7.000K
YoY Change 8314.29% -30.0%
Acquisitions
YoY Change
Other Investing Activities -$183.3M
YoY Change
Cash From Investing Activities -$183.9M -$7.000K
YoY Change 2627342.86% -30.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 80.00K 778.0K
YoY Change -89.72% -99.26%
NET CHANGE
Cash From Operating Activities -20.67M -5.135M
Cash From Investing Activities -183.9M -7.000K
Cash From Financing Activities 80.00K 778.0K
Net Change In Cash -204.5M -4.364M
YoY Change 4586.41% -104.54%
FREE CASH FLOW
Cash From Operating Activities -$20.67M -$5.135M
Capital Expenditures $589.0K $7.000K
Free Cash Flow -$21.26M -$5.142M
YoY Change 313.52% -42.69%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001810182
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-39386
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
ALX ONCOLOGY HOLDINGS INC
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0642577
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
323 Allerton Avenue
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2022Q1 dei City Area Code
CityAreaCode
650
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
466-7125
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
ALXO
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40680947
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159086000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
363667000
CY2022Q1 us-gaap Short Term Investments
ShortTermInvestments
157510000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4929000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3352000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
321525000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
367019000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1338000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
897000
CY2022Q1 us-gaap Long Term Investments
LongTermInvestments
25109000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15704000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12267000
CY2022Q1 us-gaap Assets
Assets
363676000
CY2021Q4 us-gaap Assets
Assets
380183000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5133000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3764000
CY2022Q1 alxo Payable And Accrued Liabilities Due To Related Party Current
PayableAndAccruedLiabilitiesDueToRelatedPartyCurrent
1446000
CY2021Q4 alxo Payable And Accrued Liabilities Due To Related Party Current
PayableAndAccruedLiabilitiesDueToRelatedPartyCurrent
1630000
CY2022Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
8729000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
9901000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
15308000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15295000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4772000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1839000
CY2022Q1 us-gaap Liabilities
Liabilities
20080000
CY2021Q4 us-gaap Liabilities
Liabilities
17134000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40656632
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40656632
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40587067
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40587067
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
41000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
41000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
570679000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
564993000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-606000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-226518000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-201985000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
343596000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
363049000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
363676000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
380183000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17073000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9849000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7674000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4359000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
24747000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
14208000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-24747000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14208000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
225000
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
25000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-24533000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-14185000
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.60
CY2021Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.35
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40616302
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40055435
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-24533000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-14185000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-606000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25139000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14185000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
363049000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
185000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5501000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-606000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-24533000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
343596000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
429845000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1024000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1800000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-14185000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
418484000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-24533000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-14185000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
58000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5000
CY2022Q1 alxo Operating Finance Lease Right Of Use Asset Amortization Expense
OperatingFinanceLeaseRightOfUseAssetAmortizationExpense
318000
CY2021Q1 alxo Operating Finance Lease Right Of Use Asset Amortization Expense
OperatingFinanceLeaseRightOfUseAssetAmortizationExpense
58000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5501000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1800000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-107000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1577000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
453000
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
317000
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
583000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1553000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7346000
CY2022Q1 alxo Increase Decrease In Payable And Accrued Liabilities Due To Related Parties Current
IncreaseDecreaseInPayableAndAccruedLiabilitiesDueToRelatedPartiesCurrent
-184000
CY2022Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1304000
CY2021Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
585000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-296000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
292000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20674000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5135000
CY2022Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
183332000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
589000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-183921000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
185000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
778000
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
105000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
80000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
778000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-204515000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4364000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
363667000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
434219000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
159152000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
429855000
CY2022Q1 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
147000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3419000
CY2021Q1 alxo Receivables For Cash In Transit On Exercise Of Common Stock Under Equity Incentive Plans
ReceivablesForCashInTransitOnExerciseOfCommonStockUnderEquityIncentivePlans
246000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159086000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
429855000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
66000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
159152000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
429855000
CY2022Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reclassifications</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Certain amounts in the prior period have been reclassified to conform to the current period presentation.</span></p>
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. On an ongoing basis, management evaluates its estimates, including those related to the estimated useful lives of long-lived assets, clinical trial accruals, fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.</span></p>
CY2022Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
25109000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
332212000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
357181000
CY2022Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
332212000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
357181000
CY2022Q1 us-gaap Cash
Cash
9500000
CY2021Q4 us-gaap Cash
Cash
6500000
CY2022Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
307103000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
357181000
CY2022Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2022Q1 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2022Q1 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2022Q1 us-gaap Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
0
CY2022Q1 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1459000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
960000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
121000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
63000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1338000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
897000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15704000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12267000
CY2022Q1 alxo Accrued Clinical And Non Clinical Costs Current
AccruedClinicalAndNonClinicalCostsCurrent
4026000
CY2021Q4 alxo Accrued Clinical And Non Clinical Costs Current
AccruedClinicalAndNonClinicalCostsCurrent
4125000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2372000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3294000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
455000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
790000
CY2022Q1 alxo Accrued Contract Manufacturing Current
AccruedContractManufacturingCurrent
460000
CY2021Q4 alxo Accrued Contract Manufacturing Current
AccruedContractManufacturingCurrent
693000
CY2022Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
429000
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
429000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
596000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
313000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
391000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
257000
CY2022Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
8729000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
9901000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5000000.0
CY2022Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
600000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
752000
CY2022Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
324000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
1013000
CY2022Q1 us-gaap Finance Lease Liability Payments Due In Next Rolling Twelve Months
FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths
288000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Two
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
1033000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Three
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
1064000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Four
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
939000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due After Rolling Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive
2145000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6946000
CY2022Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
612000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1730000
CY2022Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
8000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
5216000
CY2022Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
604000
CY2022Q1 alxo Operating Lease Liability Current Including Payable And Accrued Liabilities Due To Related Party
OperatingLeaseLiabilityCurrentIncludingPayableAndAccruedLiabilitiesDueToRelatedParty
620000
CY2022Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
429000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4596000
CY2022Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
175000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
5216000
CY2022Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
604000
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y8M12D
CY2022Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y4M24D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.078
CY2022Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.017
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
249000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
36000
CY2022Q1 alxo Variable Lease Cost And Other Net
VariableLeaseCostAndOtherNet
52000
CY2021Q1 alxo Variable Lease Cost And Other Net
VariableLeaseCostAndOtherNet
22000
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
44000
CY2021Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
3000
CY2022Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
112000
CY2021Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
23000
CY2022Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
3000
CY2021Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1000
CY2022Q1 us-gaap Lease Cost
LeaseCost
460000
CY2021Q1 us-gaap Lease Cost
LeaseCost
85000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
169000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
23000
CY2022Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
3000
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
105000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40656632
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40587067
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11302223
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5501000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1800000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-24533000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-14185000
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40616302
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40055435
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.60
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5456857
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4352067
CY2022Q1 alxo Number Of Pending Or Threatened Litigation
NumberOfPendingOrThreatenedLitigation
0

Files In Submission

Name View Source Status
0000950170-22-008499-index-headers.html Edgar Link pending
0000950170-22-008499-index.html Edgar Link pending
0000950170-22-008499.txt Edgar Link pending
0000950170-22-008499-xbrl.zip Edgar Link pending
alxo-20220331.htm Edgar Link pending
alxo-20220331.xsd Edgar Link pending
alxo-20220331_cal.xml Edgar Link unprocessable
alxo-20220331_def.xml Edgar Link unprocessable
alxo-20220331_htm.xml Edgar Link completed
alxo-20220331_lab.xml Edgar Link unprocessable
alxo-20220331_pre.xml Edgar Link unprocessable
alxo-ex31_1.htm Edgar Link pending
alxo-ex31_2.htm Edgar Link pending
alxo-ex32_1.htm Edgar Link pending
alxo-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending